Advertisement

Advances in Therapy

, Volume 33, Issue 7, pp 1199–1214 | Cite as

Comprehensive Study of Patients’ Compliance with Sublingual Immunotherapy in House Dust Mite Perennial Allergic Rhinitis

  • Alfonso Malet
  • Angel Azpeitia
  • Diego Gutiérrez
  • Francisco Moreno
  • María del Mar San Miguel Moncín
  • José Angel Cumplido
  • Magdalena Lluch
  • Eva BaróEmail author
  • Albert Roger
Original Research

Abstract

Introduction

Allergen immunotherapy is a long-term treatment that has been associated with patient adherence issues. The aim of the study was to increase the knowledge on compliance of patients allergic to house dust mites, receiving sublingual immunotherapy (SLIT).

Methods

A retrospective observational study was performed in 53 Spanish allergy units. We enrolled patients undergoing the SLIT treatment for house dust mites including a scheduled control visit 12 months after initiating the therapy. We conducted a comprehensive assessment of compliance using three methods. In the first step, an allergist evaluated the patients according to the results of an interview and the existing medical records. The subjects taking more than 80% of the overall prescription were defined as compliant. The remaining noncompliant patients were divided into groups taking less than 25%, 25–50%, and 50–80% of the prescribed SLIT. In the second stage, we conducted the Morisky–Green test. Finally, the noncompliant patients were asked to fill a self-report assessment form. Data were stratified into age groups. The potential factors affecting compliance were also investigated.

Results

Overall, 380 subjects participated in the study. The compliance rate was 79.7%, and the treatment discontinuation rate was 22.5%, while 66.8% of patients were adherent (both compliant and continuing with the treatment). The results showed that children were the most compliant and adolescents the least compliant (86.6% and 60.9%, respectively). The main reason for noncompliance was “forgetting some doses” in 31.0% of the children, 48.0% of the adolescents, and 53.2% of the adults. Compliance was associated with the following factors: age, number of annual control visits, and reduction in symptomatic medication.

Conclusion

Our results showed that two out of three patients with house dust mite-induced allergic rhinitis adhered to the SLIT treatment. Multidisciplinary and integral solutions are needed to improve the compliance, with special attention paid to adolescents.

Funding

Stallergenes Greer Spain.

Keywords

Allergy Adherence Allergen immunotherapy Pulmonary Respiratory Treatment interruption Sublingual immunotherapy 

Notes

Acknowledgments

Sponsorship and article processing charges for this study were funded by Stallergenes Greer Spain. All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. Editorial assistance in the preparation of this manuscript was provided by Irantzu Izco-Basurko. Support for this assistance was funded by Stallergenes Iberica.

Disclosures

Alfonso Malet, Angel Azpeitia, Diego Gutiérrez, Francisco Moreno, María del Mar San Miguel Moncín, José Angel Cumplido, Magdalena Lluch, Eva Baró, and Albert Roger have nothing to disclose.

Compliance with Ethics Guidelines

All procedures were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients included in the study.

References

  1. 1.
    Radulovic S, Calderón MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;12:CD002893. doi: 10.1002/14651858.CD002893.pub2.PubMedGoogle Scholar
  2. 2.
    Sikora JM, Tankersley MS, ACAAI Immunotherapy and Diagnostics Committee. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey. Ann Allergy Asthma Immunol. 2013;110(3):194–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Erny-Albrecht K, Valentine WJ, Christensen J, Roze S, Cobden D, Palmer AJ. Sublingual immunotherapy in allergic rhinitis and asthma: a review of recent clinical evidence. J Appl Res. 2007;7(1):17–31.Google Scholar
  4. 4.
    World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. In: Bousquet J, Lockey R, Malling HJ, editors. Allergy 1998; 53(suppl.):1–33, 43.Google Scholar
  5. 5.
    Bousquet J, Khaltaev N, Cruz AA, Papadopoulos NG, Bousquet PJ, Burney PG. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):S8–160.CrossRefGoogle Scholar
  6. 6.
    Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2013 update. Allergy. 2009;64(Suppl. 91):1–59.PubMedGoogle Scholar
  7. 7.
    Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol. 2007;120(Suppl. 3):S25–85.Google Scholar
  8. 8.
    Christensen AJ. Patient adherence to medical treatment regimens: bridging the gap between behavioral science and biomedicine. Current perspectives in psychology series. New Haven: Yale University Press; 2004.Google Scholar
  9. 9.
    Sabaté E, editor. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization. 2003. http://whqlibdoc.who.int/publications/2003/9241545992.pdf. Accessed 10 May 2016.
  10. 10.
    Köberlein J, Kothe A, Schaffert C. Determinants of patient compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11(3):192–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy. 2013;43(1):22–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Aboshady OA, Elghanam KM. Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence and guidelines. Clin Exp Otorhinolaryngol. 2014;7(4):241–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC. Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. Allergy. Clin Immunol. 2013;132(2):353–60.Google Scholar
  14. 14.
    Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers’ viewpoint. J Allergy Clin Immunol. 2010;126(3):668–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Chang H, Han DH, Mo J, Kim JW, Kim DY, Lee CH, et al. Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites. Clin Exp Otorhinolaryngol. 2009;2(3):136–40.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy. 2010;65(5):668–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco AD, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101(2):206–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Passalacqua G, Musarra A, Pecora S, Amoroso S, Antonicelli L, Cadario G, et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol. 2007;18(1):58–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Passalacqua G, Musarra A, Pecora S, Amoroso S, Antonicelli L, Cadario G, et al. Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). J Allergy Clin Immunol. 2006;117(4):946–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW, et al. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol. 2004;113(6):1219–20.CrossRefPubMedGoogle Scholar
  21. 21.
    Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy. 2004;59(11):1205–10.CrossRefPubMedGoogle Scholar
  22. 22.
    Köberlein J, Kothe AC, Sieber J, Mösges R. Determining factors of patient compliance to treatment in allergic rhinitis. Asian Pac J Allergy Immunol. 2013;31(2):148–56.CrossRefPubMedGoogle Scholar
  23. 23.
    Pajno GB, Vita D, Caminiti L, et al. Children’s compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol. 2005;116(6):1380–1.CrossRefPubMedGoogle Scholar
  24. 24.
    The global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention. 2016. http://ginasthma.org/2016-pocket-guide-for-asthma-management-and-prevention/. Accessed 10 May 2016.
  25. 25.
    Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.CrossRefPubMedGoogle Scholar
  26. 26.
    Valero A, Ferrer M, Baro E, Sastre J, Navarro AM, Martí-Guadaño E, et al. Discrimination between moderate and severe disease may be used in patients with either treated or untreated allergic rhinitis. Allergy. 2010;65(12):1609–13.CrossRefPubMedGoogle Scholar
  27. 27.
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.CrossRefPubMedGoogle Scholar
  28. 28.
    Val Jiménez A, Amorós Ballestero G, Martínez Visa P, Fernández Ferré ML, León Sanromà M. Estudio descriptivo del cumplimiento del tratamiento farmacológico antihipertensivo y validación del test Morisky y Green. Aten Primaria. 1992;10(5):767–70.PubMedGoogle Scholar
  29. 29.
    WHO. Adherence to long-term therapies: evidence for action. WHO/MNC/03.01.Google Scholar
  30. 30.
    SPSS. Statistical Package for the Social Sciences. Version 13.Google Scholar
  31. 31.
    Lee S, Nolte H, Benninger MS. Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis. Am J Rhinol Allergy. 2015;29(2):106–14.CrossRefPubMedGoogle Scholar
  32. 32.
    Fitzgerald D. Non-compliance in adolescents with chronic lung disease: causative factors and practical approach. Paediatr Respir Rev. 2001;2(3):260–7.PubMedGoogle Scholar
  33. 33.
    Incorvaia C, Rapetti A, Scurati S, Puccinelli P, Capecce M, Frati F. Importance of patient’s education in favoring compliance with sublingual immunotherapy. Allergy. 2010;65(10):1341–2.CrossRefPubMedGoogle Scholar
  34. 34.
    Bernaola G, Corzo JL, Domínguez-Ortega J, Lucas C, Ojeda I, Torres-Borrego J, et al. Sublingual immunotherapy: factors influencing adherence. J Investig Allergol Clin Immunol. 2012;22(6):458–9.PubMedGoogle Scholar
  35. 35.
    Taddeo D, Eggedy M, Frappier JY. Adherence to treatment in adolescents. Paediatr Child Health. 2008;13(1):19–24.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35(5):565–71.CrossRefPubMedGoogle Scholar
  37. 37.
    Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006;119(4 Suppl 1):S32–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566–77.CrossRefPubMedGoogle Scholar
  39. 39.
    Strandbygaard U, Thomsen SF, Backer V. A daily SMS reminder increases adherence to asthma treatment: a three-month follow-up study. Respir Med. 2010;104(2):166–71.CrossRefPubMedGoogle Scholar
  40. 40.
    Bender BG. Motivating patient adherence to allergic rhinitis treatments. Curr Allergy Asthma Rep. 2015;15(3):10.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare 2016

Authors and Affiliations

  • Alfonso Malet
    • 1
  • Angel Azpeitia
    • 2
  • Diego Gutiérrez
    • 3
  • Francisco Moreno
    • 4
  • María del Mar San Miguel Moncín
    • 5
  • José Angel Cumplido
    • 6
  • Magdalena Lluch
    • 1
  • Eva Baró
    • 7
    Email author
  • Albert Roger
    • 8
  1. 1.Al.lergo CentreBarcelonaSpain
  2. 2.Medical DepartmentStallergenes IbericaBarcelonaSpain
  3. 3.Servicio Neumologia-AlergiaPuerta del Mar HospitalCádizSpain
  4. 4.Doctor Lobatón ClinicCádizSpain
  5. 5.Allergy Unit, Pius Hospital de VallsXarxa Santa TeclaTarragonaSpain
  6. 6.Doctor Negrín University HospitalGran CanariaSpain
  7. 7.Health Outcomes Research Department3D HealthBarcelonaSpain
  8. 8.Allergy UnitGermans Trias i Pujol HospitalBadalonaSpain

Personalised recommendations